Drug costs are too high, lawmakers agreed at a Senate committee hearing this week. But industry pushback and delays have stalled reform of a system experts say is rigged.
Congress isn’t quite done pointing a finger at drugmakers and pharmacy benefit managers for their roles in the prescription drug affordability crisis. But members of the Senate Judiciary Committee acknowledged on Tuesday the three fingers aimed back at them.
“I am embarrassed that my side has been in control for two years, and we've done nothing. Zero, zilch, nada,” Sen. John Kennedy, R-La., said during the hearing.
Although the Senate committee advanced six bipartisan bills last year aimed at lowering drug costs, only one bill – the Affordable Prescriptions for Patients Act, which would limit how many brand-name biologic patents a drugmaker can use to sue companies making lower-cost biosimilars – made it to the Senate floor.
Judiciary Chairman Chuck Grassley, R-Iowa, said it wasn’t clear why the bills have stalled, although a crowded legislative calendar and strong industry pushback likely contributed.
The lack of reform from the Republican-led Congress comes despite President Donald Trump’s interest in lowering drug prices. Trump launched his own platform earlier this year for people to buy drugs directly from manufacturers at discounted rates similar to Mark Cuban’s Cost Drug Plus Company.
Still, lawmakers at the hearing said addressing exorbitant drug costs remains a bipartisan issue, with both sides of the aisle calling explicitly for legislative action on PBM reform and the stalled bills.
Passing the six bills cleared by the committee last year – which tackle patient and regulatory loopholes that have allowed PBMs and drugmakers to maximize profits, as well as PBM self-dealing and vertical integration – should be a priority, industry experts said at the hearing.
Source link







